A phase 1, open-label study to characterize the absorption, metabolism and excretion of 14C-JNJ-63623872 after a single dose in healthy male subjects

Completed

• Conditions: Influenza A; RNA-virus; 10047438

• Registration Number: NL-OMON42724
• Lead Sponsor: Janssen-Cilag

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 6

Inclusion Criteria

Healthy male subjects
18-60 years, inclusive
BMI: 18.0-30.0 kg/m2 inclusive

Exclusion Criteria

Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary objective is to characterize the absorption and metabolic pathways<br /><br>of JNJ-63623872, and the excretion of the compound and its metabolites, after<br /><br>single oral dosing of 14C-JNJ-63623872 in healthy adult male subjects.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary objective of this study is to determine safety and tolerability<br /><br>for a single oral dose of 14C-JNJ-63623872 in healthy adult male subjects.</p><br>